Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number of new agents have been approved for RCC, several of which attack tumor angiogenesis by inhibiting vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR), as well as tumor metabolism, inhibiting the mammalian target of rapamycin (mTOR). Additionally, a new class of immunotherapy agents, immune checkpoint inhibitors, is emerging and will play a significant role in the treatment of patients with RCC. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a Task Force, which met to consider the current role of approved immunotherapy agents in RCC, to provide guidance to practicing clinicians by developing consensus recommendations and to set the stage for future immunotherapeutic developments in RCC.

Journal for immunotherapy of cancer. 2016 Jan 15*** epublish ***

Brian I Rini, David F McDermott, Hans Hammers, William Bro, Ronald M Bukowski, Bernard Faba, Jo Faba, Robert A Figlin, Thomas Hutson, Eric Jonasch, Richard W Joseph, Bradley C Leibovich, Thomas Olencki, Allan J Pantuck, David I Quinn, Virginia Seery, Martin H Voss, Christopher G Wood, Laura S Wood, Michael B Atkins

Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Cleveland, OH 44195 USA., Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, 10 Highfield Circle, Milton, MA 02186 USA., Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans St, Baltimore, MD 21287 USA., Kidney Cancer Association, PO Box 4668 #38269, Chicago, IL 60680 USA., Cleveland Clinic Taussig Cancer Institute, 1 Clinic Center, Cleveland, OH 44195 USA., Patient and Patient Advocate, Cleveland, USA., Cedars-Sinai Medical Center, 8700 Beverly Blvd., Saperstein Critical Care Tower, 1S28, Los Angeles, CA 90048 USA., Charles A. Sammons Cancer Center, Baylor University Medical Center, 3410 Worth Street, Suite 400, Dallas, TX 75254, USA., M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA., Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA., Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA., The Ohio State University Medical Center, 320 W. 10th Avenue, Columbus, OH 43210, USA., UCLA Institute of Urologic Oncology, 66-124 Center for Health Sciences, Los Angeles, CA 90095, USA., Kenneth J. Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Ave Suite 3451, Los Angeles, CA 90033, USA., Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA., Georgetown-Lombardi Comprehensive Cancer Center, 3970 Reservoir Road, NW, Research Building, Room E501, Washington, DC 20057, USA.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe